Evan Stein, MD, PhD
Metabolic & Atherosclerosis Research Center
Harry Leider, MD, MBA
Chief Medical Officer
CME and CPE, 1 hour
This is the
second program in a two-part series based on previously presented live audioconferences.
By taking a proactive, disease-management approach, managed care has demonstrated high success rates in delivering expense reduction and superior health outcomes in several therapeutic areas. Since heart disease represents perhaps the single most costly item on the healthcare inventory, it makes sense to focus on preventive treatments that will reduce or delay expensive cardiovascular events such as myocardial infarction, percutaneous intervention, or heart failure. Cost-effectiveness studies have shown substantial savings per life-year for each high-risk dyslipidemia patient who is taking an HMG-CoA reductase inhibitor (“statin”) and is appropriately treated to their low-density lipoprotein cholesterol (LDL-C) goal. Lower-risk patients also demonstrated substantial healthcare savings. To be effective, however, the barriers to optimal LDL control (ineffective dose and drug selection, questions about safety, inadequate monitoring) must be identified and tools to enhance physician knowledge, patient compliance, and cost effectiveness must be used. This online program will examine the barriers against effective treatment and will outline strategies for overcoming the obstacles and enhancing the cost effectiveness and economic benefit of successful dyslipidemia treatment. Program Developer/Facilitator
. Target Audience
Managed Care Medical Directors, Pharmacy Directors, and other physicians and pharmacists interested in the management of dyslipidemia.
Upon completion of this educational activity, the participant should be able to:
Define barriers to achieving and maintaining long-term LDL-C control.
List tools and strategies to enhance treatment selection, compliance, and cost effectiveness.
Outline strategies, from a managed care perspective, for effectively managing dyslipidemia patients of varying ages, comorbidities, and risk profiles.
It is the policy of AKH Inc. to ensure independence, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
Dr. Stein discloses that he has received product consultation, advisory comittee, and speakers' bureau fees from AstraZeneca.
Dr. Leider discloses that his employer, XLHealth, is a disease management company that provides services to managed care organizations.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should only claim credit commensurate with the extent of their participation in the activity. TM
AKH Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been assigned the Universal Program Number 077-999-07-077-H01 and is acceptable for 1.0 contact hour (0.1 CEUs) in states that recognize ACPE-approved providers.
Participants must successfully complete the post-test (70% or higher) and submit an evaluation to receive credit.
Commercial Support Statements
This program is supported by an educational grant from AstraZeneca.
Please turn off all pop-up blockers.
Click on the “start program” icon. This will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or update/correct existing registration information. When ready, click on the “continue to program” icon at the bottom of the screen. This will take you to a brief pre-program survey.
The next screen will permit you to check for or download the Flash player required to run this program.
Clicking “start the virtual meeting” will allow you to begin the program presentation.
Upon completion of the program, click on the post-test button to access the post-test and program evaluation. This will bring you to a brief post-program survey.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CPE statement of credit. Two attempts are allowed.
None of the contents of this activity may be reproduced in any form without prior written permission of the publisher. The opinions expressed in this activity are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or AstraZeneca. Any medications, or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and of possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.